Acadia confirms plan to request CHMP re-examination
Filed with ASX · · 2 pages · English
Neuren Pharmaceuticals Limited on 6ix
Earlier from Neuren Pharmaceuticals
- 2025 royalty income A$65m, profit after tax A$30m
- Appendix 4E and 2025 full year accounts
- Acadia reports DAYBUE net sales for 2025 and 2026 guidance
- Pause in Trading
- Neuren to commence new on-market share buy-back program
Later from Neuren Pharmaceuticals
- DAYBUE STIX now broadly available in US for Rett syndrome
- Q1 2026 DAYBUE net sales US$101m, up 20% from Q1 2025
- DAYBU recommended for approval in the European Union
- Record Q2 DAYBUE net sales of US$125m, CY26 royalty upgraded
- European Commission grants marketing authorisation for DAYBU
Follow Neuren Pharmaceuticals into a list and get an email when it puts out news.
Follow Neuren Pharmaceuticals